TG Therapeutics Inc. stocks have been trading up by 11.61 percent following upbeat sentiment on its multiple sclerosis drug prospects.
Key Takeaways For TGTX Traders
- Q2 2026 revenue hit about $240M, with U.S. BRIUMVI sales up 64% year over year to $227.7M and full-year 2026 guidance raised to ~$950M.
- Earnings per share were $0.05, missing consensus even as TGTX revenue of roughly $240.3M topped expectations around $229.8M and grew about 70% year over year.
- TG Therapeutics stayed profitable, ended Q2 with $612M in cash, and guided to exiting 2026 at about a $1B annualized U.S. BRIUMVI revenue run rate.
- Positive Phase 3 ENHANCE data and a Phase 3 subcutaneous BRIUMVI program extend TGTX’s MS franchise and broader immune‑disease platform.
- B. Riley lifted its TGTX price target to $86 and Street targets average $64, even after shares slid about 10.6% to $46.52 following the earnings release.
Live Update At 12:32:04 EDT: On Friday, August 21, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 11.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TG Therapeutics, trading as TGTX, just showed why biotech is a rollercoaster. On the fundamentals side, the Q2 2026 report was strong. Revenue came in around $240.3M, up roughly 70% year over year, powered mainly by BRIUMVI, the company’s multiple sclerosis drug. U.S. BRIUMVI sales reached $227.7M, up 64% versus last year, showing serious traction in the MS market.
Margins are eye‑catching. TGTX reported a gross margin near 92.7%, which is what you want to see in a high‑value drug franchise. Operating income was about $21.7M, and the company still printed positive net income around $7.8M despite pouring money into R&D and sales. For a commercial‑stage biotech, staying profitable while scaling is a big deal.
The balance sheet backs that up. Cash and equivalents stand near $482.6M, with total cash and short‑term investments around $552.2M and working capital close to $877.2M. TGTX carries long‑term debt near $752.5M, but an interest‑coverage ratio around 2.5 and a current ratio of 4.3 suggest the company can comfortably service obligations.
On the chart, TGTX has bounced sharply. After dumping to $46.52 on the earnings reaction, it has ripped back to close near $56.45 on 2026/08/21, reclaiming and then extending above the early‑August selloff zone.
More Breaking News
Intraday on the latest session, TGTX held a strong trend. The stock opened at $51.10, quickly pushed through $52, and never revisited the premarket lows. Through the morning, buyers stepped in on every dip near the mid‑$55s. By midday, TGTX was trading in a tight band around $56, with higher lows holding from 10:00 onward, a classic intraday uptrend with controlled pullbacks rather than panic spikes.
Why Traders Are Locked In On TGTX
This entire TGTX move revolves around one word: BRIUMVI. Q2 2026 numbers confirmed the drug is not just launching well, it is scaling. U.S. BRIUMVI revenue of $227.7M drove total quarterly revenue to roughly $240M, and that strength gave management confidence to raise 2026 total revenue guidance to about $950M. They now expect to exit 2026 with roughly a $1B annualized U.S. BRIUMVI run rate. For traders, that kind of long‑term visibility is rare in biotech.
At the same time, the market punished TGTX on the headline earnings miss. EPS landed at $0.05 versus consensus estimates that ranged from $0.31 to $0.44. That disconnect triggered an initial drop of about 10.6%, taking shares down $5.51 to $46.52 on 2026/08/03. Many algos key off EPS versus consensus, so the first move was straight down despite the revenue beat.
Under the hood, though, the story is more bullish. TGTX stayed profitable and still ended the quarter with $612M in cash, even while R&D and SG&A rose for subcutaneous BRIUMVI manufacturing and pipeline expansion. Positive Phase 3 ENHANCE data for a simplified single‑infusion IV start, plus a Phase 3 subcutaneous program, signal that TGTX is working to lock in its MS franchise for the long haul. Expansion moves into myasthenia gravis and schizophrenia show management thinking beyond a single indication.
Wall Street is noticing. B. Riley raised its TGTX price target to $86 from $55 and reiterated a Buy rating. FactSet data show an average Buy stance and a mean target around $64. With TGTX recently trading near the mid‑$50s, the Street still sees upside based on BRIUMVI momentum and the upgraded guidance.
Technically, that sets up a classic “fundamentals good, chart volatile” scenario that active traders love. The sharp earnings flush created a gap between TGTX’s improving fundamentals and its price. The snap‑back toward the mid‑$50s shows dip buyers are already probing that gap.
Conclusion
For active traders, TGTX is a live case study in how growth, guidance, and expectations collide. On one side, TG Therapeutics raised its 2026 revenue outlook to roughly $950M, driven by a powerful BRIUMVI ramp, strong gross margins, and a pipeline that is pushing into new formulations and diseases. Cash of more than $600M and ongoing profitability give TGTX room to keep spending aggressively without immediate funding pressure.
On the other side, the market reminded everyone that earnings expectations still matter. The $0.05 EPS print versus higher Street targets set off a swift 10.6% post‑earnings drop before TGTX clawed its way back above $56. That whipsaw shows sentiment can swing fast when a high‑expectation name stumbles on the bottom line, even as revenue beats and guidance rise.
Traders in the Tim Sykes community focus on exactly this kind of setup: strong catalysts, big gaps, and clear levels. TGTX has them all right now. As Tim Sykes often says, “Volatility is a gift, but only if you respect it and cut losses quickly.” As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Applied to TGTX, that means respecting both the bullish BRIUMVI trajectory and the reality that any stumble on execution, data, or guidance can trigger another sharp downdraft.
This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply